Nohla Therapeutics R
Nohla Therapeutics Receives FDA Orphan Drug Designation for Dilanubicel for Hematopoietic Stem Cell Transplant Patients
July 16, 2018 13:30 ET | Nohla Therapeutics
SEATTLE, July 16, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
Nohla Announces Pres
Nohla Announces Presentation of Dilanubicel (NLA101) Data at EHA Annual Meeting Showcasing Excellent Long-term Survival Outcomes
June 15, 2018 11:30 ET | Nohla Therapeutics
SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
Nohla Receives EMA P
Nohla Receives EMA PRIME Designation for Dilanubicel (NLA101) to Treat Hematopoietic Stem Cell Transplant Patients
June 06, 2018 13:00 ET | Nohla Therapeutics
SEATTLE, June 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...